Jul 2012

Home >> Clinical Trials News Archive >> 2012 >> Jul 2012
Venture capital investment in life sciences down 9%. Despite venture capitalists investing $7 billion in 898 deals in the second quarter of 2012—a 17% climb in terms of dollars and an 11% rise in the number of deals compared to the first quarter of 2012, when $6 billion was invested in 809 deals—the life sciences sector (biotechnology and medical devices) saw a 9% drop in funding dollars and a 6% drop in deals from the prior quarter, to $1.4 billion going into 174 deals in Q2.
U.S. generic drugmaker Perrigo to Invest $40 Million in Israel over the next three years to expand its R&D and production here. As part of the investment, Perrigo plans to add another 100 employees to its two plants in Israel, it said. Perrigo has expanded its workforce in Israel by 40% over the past three years to about 900 people. Global sales in 2011 were $2.76 billion. Most of the products developed and manufactured in Israel are shipped to the United States and Europe.
Life Sciences Baltics Sept.12-14. Nobel-prize winner Prof. Ada Yonath will head a delegation of about 100 Israeli participants to the Life Sciences Baltics 2012 (www.lsb2012.com) conference in Vilnius, Lithuania Sept.12-14. The conference will showcase the rapidly growing life science industries of Lithuania, Estonia and Latvia and will include partnering events and company visits.